These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33350353)

  • 21. An update on dengue vaccine development, challenges, and future perspectives.
    Idris F; Ting DHR; Alonso S
    Expert Opin Drug Discov; 2021 Jan; 16(1):47-58. PubMed ID: 32838577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting.
    Lam SK; Burke D; Capeding MR; Chong CK; Coudeville L; Farrar J; Gubler D; Hadinegoro SR; Hanna J; Lang J; Lee HL; Leo YS; Luong CQ; Mahoney R; McBride J; Mendez-Galvan J; Ng LC; Nimmannitya S; Ooi EE; Shepard D; Smit J; Teyssou R; Thomas L; Torresi J; Vasconcelos P; Wirawan DN; Yoksan S
    Vaccine; 2011 Nov; 29(51):9417-22. PubMed ID: 21864627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
    Norshidah H; Vignesh R; Lai NS
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal age of vaccination against dengue in Brazil based on serotype-specific forces of infection derived from serological data.
    Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D
    Math Med Biol; 2021 Mar; 38(1):1-27. PubMed ID: 32671383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue vaccines: what we know, what has been done, but what does the future hold?
    Abrão EP; Espósito DL; Lauretti F; da Fonseca BA
    Rev Saude Publica; 2015; 49():60. PubMed ID: 26398877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
    Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
    Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sanofi’s successful Phase 3 trials may lead to first-ever dengue vaccine in 2015.
    Hum Vaccin Immunother; 2014; 10(12):3427. PubMed ID: 25864560
    [No Abstract]   [Full Text] [Related]  

  • 30. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementing a dengue vaccination programme-who, where and how?
    E Clapham H; A Wills B
    Trans R Soc Trop Med Hyg; 2018 Aug; 112(8):367-368. PubMed ID: 30016491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wanted Dead or Alive: A Correlate of Protection Against Dengue Virus.
    Gil L; Martín A; Lazo L
    Front Immunol; 2019; 10():2946. PubMed ID: 31921194
    [No Abstract]   [Full Text] [Related]  

  • 33. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dengue vaccines: challenges, development, current status and prospects.
    Ghosh A; Dar L
    Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioethics of establishing a CHIM model for dengue vaccine development.
    Rose A; Sekhar A
    Int J Infect Dis; 2019 Jul; 84S():S74-S79. PubMed ID: 30641207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dengue vaccine: a key for prevention.
    Thisyakorn U; Tantawichien T
    Expert Rev Vaccines; 2020 Jun; 19(6):499-506. PubMed ID: 32452272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trolleyology and the Dengue Vaccine Dilemma.
    Rosenbaum L
    N Engl J Med; 2018 Jul; 379(4):305-307. PubMed ID: 29898371
    [No Abstract]   [Full Text] [Related]  

  • 38. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate.
    Lazo L; Valdes I; Guillén G; Hermida L; Gil L
    Expert Rev Vaccines; 2019 Feb; 18(2):161-173. PubMed ID: 30677305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
    Harenberg A; de Montfort A; Jantet-Blaudez F; Bonaparte M; Boudet F; Saville M; Jackson N; Guy B
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004830. PubMed ID: 27459266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.